Innovative Technology to Automate and Improve the Detection Sensitivity of Ultra-low Frequency Mutations Directly from Blood Liquid Biopsies
Blood liquid biopsy contains circulating cell-free DNA (cfDNA), a portion of which may be shed from tumors. This tumor-derived
cfDNA, or circulating tumor DNA (ctDNA), can be analysed to detect cancers and identify their mutation profiles. Sensitive and specific
cancerous mutation detection is critical to guide selection of the correct treatment regimens and lead to improved patient outcomes1.
DNAe is developing the first rapid, sample-to-result, next-generation sequencing (NGS)-based platform, the LiDia-SEQ™ platform, which
enables clinically relevant NGS ctDNA analysis and reporting within a work shift for use in routine clinical care. The whole workflow is
fully automated.
